In what could open the door to a potential cure for multiple  myeloma, Swedish scientists have discovered that a single antibody — a  protein used by the immune system to fight infection and disease — could  be the key to treating the cancer of the blood, which now has no  effective long-term treatment.
 
Researchers at Lund University in Sweden tested thousands of  antibodies to identify one in particular — known as BI-505 — that they  said was shown to have “a powerful effect on the tumor cells in both  cell studies and animal experiments.” Preliminary tests of BI-505 on  seriously ill patients also found it to be safe, and another study of  its treatment effects on newly diagnosed individuals has just begun. 
 
“We tested the antibody in various ways, including on tumor cells  from myeloma patients that have been transplanted into mice,” said Lund  researcher Markus Hansson. “The tests showed that the antibody is able  to destroy myeloma cells.”
 
Special: This Small Group of Doctors is Quietly Curing CancerMyeloma develops when cells in the bone marrow become cancerous,  disrupting blood formation and resulting in fatigue, weakened bones, and  life-threatening  kidney failure. Several drugs are currently used to  treat multiple myeloma, but none eradicate the disease. There is no  cure. Fewer than half of all patients diagnosed with the condition live  longer than five years.
 
Drugs based on antibodies, which are a part of the immune system  and fight off foreign bodies, are a promising new line of medical  research and are now used to treat some inflammatory diseases and types  of cancer.
 
The new Lund study will involve 15 patients and is expected to be  completed this year. If the results are promising, Hansson and his  colleagues will test BI-505 in larger studies designed to uncover the  best way of using the new antibody — alone or in combination with other  drugs.
 
No comments:
Post a Comment